^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CCND1 overexpression

i
Other names: CCND1, BCL1, D11S287E, PRAD1, U21B31, Cyclin D1
Entrez ID:
Related biomarkers:
Phase 2
Merck Sharp & Dohme LLC
Recruiting
Last update posted :
02/26/2024
Initiation :
04/05/2021
Primary completion :
03/19/2027
Completion :
03/19/2027
TP53 • CCND1 • CD4
|
TP53 mutation • Chr t(11;14) • CCND1 overexpression
|
nemtabrutinib (MK-1026)
Phase 2
AbbVie
Recruiting
Last update posted :
02/22/2024
Initiation :
06/14/2022
Primary completion :
11/26/2032
Completion :
11/26/2032
BCL2 • CD20 • CCND1 • BCL6
|
Chr t(11;14) • CCND1 overexpression
|
Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • Epkinly (epcoritamab-bysp) • Polivy (polatuzumab vedotin-piiq) • golcadomide (CC-99282)
Phase 2
City of Hope Medical Center
Active, not recruiting
Last update posted :
02/15/2024
Initiation :
05/13/2020
Primary completion :
06/27/2024
Completion :
06/27/2024
BCL2 • CCND1 • FCER2
|
Chr t(11;14) • CCND1 overexpression
|
Copiktra (duvelisib) • ETP-47187
Phase 2
Nordic Lymphoma Group
Active, not recruiting
Last update posted :
02/12/2024
Initiation :
12/15/2021
Primary completion :
01/01/2027
Completion :
01/01/2027
CCND1
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Rituxan (rituximab) • Calquence (acalabrutinib)
Phase 1/2
Han weidong
Recruiting
Last update posted :
02/07/2024
Initiation :
12/15/2020
Primary completion :
12/30/2024
Completion :
12/30/2025
BCL2 • CCND1 • BCL6
|
Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
|
cyclophosphamide • decitabine • fludarabine IV
Phase 3
Hoffmann-La Roche
Recruiting
Last update posted :
01/31/2024
Initiation :
10/22/2023
Primary completion :
02/02/2026
Completion :
12/31/2026
CCND1
|
Chr t(11;14) • CCND1 overexpression
|
Rituxan (rituximab) • lenalidomide • Gazyva (obinutuzumab) • bendamustine • Actemra IV (tocilizumab) • Columvi (glofitamab)
Phase 2
Acerta Pharma BV
Active, not recruiting
Last update posted :
01/23/2024
Initiation :
03/02/2015
Primary completion :
12/04/2020
Completion :
09/01/2026
CCND1
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Calquence (acalabrutinib)
Phase 1
M.D. Anderson Cancer Center
Recruiting
Last update posted :
01/23/2024
Initiation :
11/18/2022
Primary completion :
03/31/2027
Completion :
03/31/2027
TP53 • CD20 • CCND1 • KMT2D • NOTCH2 • BIRC3 • FAT1 • POT1 • NSD2 • UBR5
|
CD20 positive • Chr t(11;14) • KMT2D mutation • BIRC3 mutation • CCND1 overexpression • SMARCA4 mutation • Chr t(11;14)(q13;q32) • MYC positive
|
Rituxan (rituximab) • cyclophosphamide • Calquence (acalabrutinib) • fludarabine IV • Tecartus (brexucabtagene autoleucel)
Phase 2
Academic and Community Cancer Research United
Recruiting
Last update posted :
01/18/2024
Initiation :
01/04/2024
Primary completion :
12/30/2029
Completion :
12/30/2030
CD19 • CCND1
|
Chr t(11;14) • CCND1 overexpression • CD19 expression • Chr t(11;14)(q13;q32)
|
Venclexta (venetoclax) • lenalidomide • Monjuvi (tafasitamab-cxix)
Phase 2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
01/17/2024
Initiation :
08/13/2019
Primary completion :
02/08/2026
Completion :
02/08/2026
CCND1
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Venclexta (venetoclax) • Calquence (acalabrutinib)
Phase 2
AstraZeneca
Recruiting
Last update posted :
01/15/2024
Initiation :
12/13/2023
Primary completion :
01/11/2029
Completion :
01/11/2029
TP53 • BCL2 • CD20 • CCND1 • PAX5 • CD5
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Venclexta (venetoclax) • Rituxan (rituximab) • Calquence (acalabrutinib)
Phase 1
City of Hope Medical Center
Active, not recruiting
Last update posted :
01/04/2024
Initiation :
03/22/2018
Primary completion :
06/22/2024
Completion :
06/22/2024
CCND1 • FCER2
|
Chr t(11;14) • CCND1 overexpression
|
Imbruvica (ibrutinib) • pevonedistat (MLN4924)
Phase 2
AstraZeneca
Active, not recruiting
Last update posted :
12/20/2023
Initiation :
11/03/2021
Primary completion :
08/22/2023
Completion :
12/31/2024
CCND1
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Truqap (capivasertib)
Phase 1/2
Incyte Corporation
Active, not recruiting
Last update posted :
12/19/2023
Initiation :
09/16/2021
Primary completion :
12/15/2024
Completion :
12/15/2024
BCL2 • CCND1 • BCL6
|
Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • BCL2 rearrangement
|
parsaclisib (INCB50465) • Monjuvi (tafasitamab-cxix)
Phase 1/2
City of Hope Medical Center
Suspended
Last update posted :
12/15/2023
Initiation :
06/29/2022
Primary completion :
11/23/2024
Completion :
11/23/2024
BCL2 • CD20 • CCND1 • PAX5 • CD5
|
Chr t(11;14) • CCND1 overexpression • PAX5 overexpression
|
Venclexta (venetoclax) • Aliqopa (copanlisib)
Phase 3
Acerta Pharma BV
Active, not recruiting
Last update posted :
12/13/2023
Initiation :
04/05/2017
Primary completion :
10/28/2025
Completion :
10/28/2025
CD20 • CCND1 • PAX5 • CD5
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Rituxan (rituximab) • Calquence (acalabrutinib) • bendamustine • Rituxan Hycela (rituximab/hyaluronidase) • Belrapzo (bendamustine RTD)
Phase 1/2
Oncternal Therapeutics, Inc
Recruiting
Last update posted :
11/30/2023
Initiation :
05/09/2023
Primary completion :
12/01/2026
Completion :
12/01/2037
CCND1
|
CCND1 overexpression
|
cyclophosphamide • ONCT-808
Phase 2
Shanghai Jiao Tong University School of Medicine
Recruiting
Last update posted :
11/22/2023
Initiation :
12/01/2016
Primary completion :
12/01/2024
Completion :
12/01/2026
CCND1
|
CCND1 overexpression • CCND1 expression • CCND1-H
|
cisplatin • docetaxel • 5-fluorouracil
Phase 2
City of Hope Medical Center
Active, not recruiting
Last update posted :
11/17/2023
Initiation :
03/26/2021
Primary completion :
07/31/2022
Completion :
09/20/2025
CD20 • CCND1
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Calquence (acalabrutinib) • Ukoniq (umbralisib) • Briumvi (ublituximab-xiiy) • rituximab biosimilar
Phase 1
Medolution Ltd.
Recruiting
Last update posted :
11/07/2023
Initiation :
09/24/2020
Primary completion :
10/10/2027
Completion :
04/10/2028
CCND1
|
CCND1 overexpression • CCND1 expression • CCND1-H
|
keynatinib (TL007)
Phase 2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
10/16/2023
Initiation :
01/25/2023
Primary completion :
04/28/2027
Completion :
04/28/2027
TP53 • MYC • BCL2 • CDKN2A • CCND1 • NOTCH2 • NSD2
|
TP53 mutation • Chr del(17p) • Chr t(11;14) • CDKN2A mutation • CCND1 overexpression • Chr t(11;14)(q13;q32) • MYC positive • BCL2 amplification
|
Venclexta (venetoclax) • Jaypirca (pirtobrutinib)
Phase 2
University College, London
Not yet recruiting
Last update posted :
10/13/2023
Initiation :
04/01/2024
Primary completion :
10/01/2028
Completion :
10/01/2028
CCND1
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Rituxan (rituximab) • Brukinsa (zanubrutinib)
Phase 3
Pharmacyclics LLC.
Active, not recruiting
Last update posted :
09/27/2023
Initiation :
06/29/2017
Primary completion :
11/15/2024
Completion :
11/15/2024
TP53 • CD20 • CCND1 • PAX5 • CD5
|
TP53 mutation • Chr t(11;14) • CCND1 overexpression • PAX5 overexpression
|
Venclexta (venetoclax) • Imbruvica (ibrutinib)
Phase 2
Dana-Farber Cancer Institute
Active, not recruiting
Last update posted :
09/21/2023
Initiation :
06/01/2014
Primary completion :
01/01/2024
Completion :
08/01/2024
PIK3CA • CD19 • CCND1 • CXCR4 • PIK3CD • CD5 • FCER2
|
Chr t(11;14) • CCND1 overexpression
|
Zydelig (idelalisib) • Arzerra (ofatumumab)
Phase 1/2
Chinese PLA General Hospital
Recruiting
Last update posted :
09/11/2023
Initiation :
09/06/2023
Primary completion :
09/01/2025
Completion :
09/01/2026
BCL2 • CCND1 • BCL6 • IL6 • TNFA • IL2 • IL10
|
CD19 positive • Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
|
cyclophosphamide • fludarabine IV • ATHENA CAR-T
Phase 2
Weill Medical College of Cornell University
Completed
Last update posted :
09/07/2023
Initiation :
07/29/2011
Primary completion :
04/01/2014
Completion :
07/30/2023
CD20 • CCND1 • CD5 • CCND2 • MME • FCER2
|
CCND1 overexpression • CCND2 overexpression
|
Rituxan (rituximab) • lenalidomide
Phase 2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
08/31/2023
Initiation :
08/07/2020
Primary completion :
06/30/2025
Completion :
06/30/2025
CD20 • CCND1
|
CD20 positive • Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Imbruvica (ibrutinib) • Calquence (acalabrutinib)
Phase 1/2
Alexey Danilov, MD
Completed
Last update posted :
08/08/2023
Initiation :
07/17/2017
Primary completion :
04/29/2021
Completion :
04/29/2021
CCND1 • FCER2
|
Chr t(11;14) • CCND1 overexpression
|
Gazyva (obinutuzumab) • entospletinib (GS-9973)
Phase 1/2
Chinese PLA General Hospital
Recruiting
Last update posted :
07/06/2023
Initiation :
06/30/2023
Primary completion :
12/15/2024
Completion :
12/15/2025
BCL2 • CCND1 • BCL6 • IL6 • TNFA • IL2 • IL10
|
CD19 positive • Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
|
cyclophosphamide • fludarabine IV • autologous TRAC locus-inserted CD19-STAR-T
Phase 1/2
Beijing InnoCare Pharma Tech Co., Ltd.
Active, not recruiting
Last update posted :
06/05/2023
Initiation :
04/02/2018
Primary completion :
12/31/2023
Completion :
12/31/2023
CCND1
|
Chr t(11;14) • CCND1 overexpression
|
Yinuokai (orelabrutinib)
Phase 1/2
Chinese PLA General Hospital
Recruiting
Last update posted :
05/15/2023
Initiation :
12/11/2022
Primary completion :
12/31/2024
Completion :
12/31/2025
BCL2 • CCND1 • BCL6 • IL6 • TNFA • IL2 • IL10
|
CD19 positive • Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
|
cyclophosphamide • fludarabine IV • Mustargen (mechlorethamine)
Phase 1/2
AstraZeneca
Active, not recruiting
Last update posted :
03/10/2023
Initiation :
04/29/2020
Primary completion :
12/22/2022
Completion :
12/29/2023
CD20 • CCND1 • PAX5 • CD5
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Calquence (acalabrutinib)
Phase 1
Dartmouth-Hitchcock Medical Center
Completed
Last update posted :
01/04/2023
Initiation :
03/09/2018
Primary completion :
01/14/2021
Completion :
01/14/2021
BCL2 • CCND1 • CD5 • FCER2
|
Chr t(11;14) • CCND1 overexpression
|
Imbruvica (ibrutinib) • BNC105
Phase 2
University College, London
Not yet recruiting
Last update posted :
11/01/2022
Initiation :
01/01/2023
Primary completion :
05/31/2026
Completion :
05/31/2026
CCND1
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Rituxan (rituximab) • Calquence (acalabrutinib)
Phase 1
Kami Maddocks, MD
Completed
Last update posted :
06/30/2022
Initiation :
07/21/2014
Primary completion :
09/12/2018
Completion :
04/09/2019
CCND1
|
CCND1 overexpression
|
Rituxan (rituximab) • buparlisib (AN2025)
Phase 2
M.D. Anderson Cancer Center
Withdrawn
Last update posted :
03/10/2022
Initiation :
11/30/2021
Primary completion :
03/24/2023
Completion :
03/24/2023
CCND1 • NOTCH2 • BIRC3 • NSD2
|
TP53 mutation • Chr del(17p) • TP53 wild-type • TP53 deletion • BIRC3 mutation • CCND1 overexpression • CCND1 mutation
|
Venclexta (venetoclax) • eprenetapopt (APR-246)
Phase N/A
Kite, A Gilead Company
Approved for marketing
Last update posted :
10/14/2021
CCND1
|
CCND1 overexpression
|
cyclophosphamide • fludarabine IV • Tecartus (brexucabtagene autoleucel)
Phase 1
Kami Maddocks
Completed
Last update posted :
07/30/2019
Initiation :
01/12/2017
Primary completion :
11/19/2018
Completion :
01/03/2019
CCND1
|
CCND1 overexpression
|
Keytruda (pembrolizumab) • Imbruvica (ibrutinib)